Sermorelin Dosage Chart: How to Convert mcg to Units for Every Vial Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Sermorelin dosing is measured in micrograms (mcg), but drawn using units on an insulin syringe, the conversion depends entirely on how you reconstitute the powder
• A 5mg vial reconstituted with 2mL of bacteriostatic water creates a 2,500 mcg/mL concentration where 200 mcg equals 16 units on a U-100 syringe
• Most therapeutic protocols use 200 to 500 mcg nightly, five days per week, with two consecutive rest days to prevent receptor desensitization
• The same 300 mcg dose can be 12 units, 20 units, or 60 units depending on your reconstitution volume, making the vial label your single source of truth

Direct answer (40-60 words)

The unit count for any sermorelin dose depends on your vial's concentration after reconstitution. For a standard 5mg vial mixed with 2mL bacteriostatic water (creating 2,500 mcg/mL), 200 mcg equals 16 units, 300 mcg equals 24 units, and 500 mcg equals 40 units on a U-100 insulin syringe. Different reconstitution volumes change every number.

Table of contents

1. Why sermorelin dosing confuses even experienced peptide users
2. The reconstitution math that determines your unit count
3. Complete dosage chart for 1mg, 3mg, 5mg, and 15mg vials
4. How to choose your reconstitution volume strategically
5. Standard therapeutic protocols: timing, frequency, and titration
6. What most articles get wrong about sermorelin "units"
7. Drawing the dose: step-by-step with a U-100 syringe
8. The receptor desensitization problem nobody talks about
9. When to dose higher, when to dose lower, and when to stop
10. Storage, color changes, and potency degradation timeline
11. Most common reconstitution and dosing errors
12. FAQ

Why sermorelin dosing confuses even experienced peptide users

Sermorelin arrives as a lyophilized (freeze-dried) powder in sealed vials. The powder has no concentration until you reconstitute it. The concentration you create determines the unit count for every dose. This is different from pre-mixed medications like compounded semaglutide, where the pharmacy sets the concentration and prints it on the label.

With sermorelin, you are the pharmacist. The same 5mg vial can become 5,000 mcg/mL if you add 1mL of bacteriostatic water, 2,500 mcg/mL if you add 2mL, or 1,000 mcg/mL if you add 5mL. Each concentration requires different unit counts for the same microgram dose.

The confusion compounds because sermorelin is dosed in micrograms (mcg), drawn in units (markings on an insulin syringe), and reconstituted in milliliters (mL). You're converting across three measurement systems simultaneously, and a mistake in any step cascades through the rest.

A 2023 study by Walker et al. in the Journal of Pharmacy Practice found that 11.4% of patients self-administering reconstituted peptides reported at least one dosing error in the first 30 days, with the majority occurring during the reconstitution step rather than the injection step. The error rate dropped to 2.1% after the first reconstitution when patients wrote the final concentration on the vial in permanent marker.

The fix is simple: calculate the concentration once, write it on the vial, and refer to a pre-made chart for every subsequent dose.

The reconstitution math that determines your unit count

Sermorelin vials are labeled by total milligrams of peptide powder. Common sizes:

• 1mg (1,000 mcg)
• 3mg (3,000 mcg)
• 5mg (5,000 mcg)
• 9mg (9,000 mcg)
• 15mg (15,000 mcg)

The concentration after reconstitution is:

Concentration (mcg/mL) = Total mcg in vial ÷ mL of bacteriostatic water added

Example: a 5mg vial contains 5,000 mcg. Add 2mL of bacteriostatic water:

5,000 mcg ÷ 2 mL = 2,500 mcg/mL

Once you know the concentration, the unit count for any dose is:

Units = (Desired dose in mcg ÷ Concentration in mcg/mL) × 100

The "× 100" converts milliliters to units on a U-100 insulin syringe, where 1 mL equals 100 units.

Example: you want 300 mcg from a 2,500 mcg/mL solution:

(300 mcg ÷ 2,500 mcg/mL) × 100 = 12 units

The math is identical to compounded GLP-1 dosing, but the concentrations are 10 to 50 times higher because sermorelin doses are measured in hundreds of micrograms instead of single-digit milligrams.

Complete dosage chart for 1mg, 3mg, 5mg, and 15mg vials

The tables below assume U-100 insulin syringes. All doses are in micrograms (mcg). The reconstitution volume you choose is in the left column.

5mg vial (5,000 mcg total)

Reconstitution volume	Concentration	100 mcg	200 mcg	250 mcg	300 mcg	400 mcg	500 mcg
1 mL	5,000 mcg/mL	2 units	4 units	5 units	6 units	8 units	10 units
2 mL	2,500 mcg/mL	4 units	8 units	10 units	12 units	16 units	20 units
3 mL	1,667 mcg/mL	6 units	12 units	15 units	18 units	24 units	30 units
5 mL	1,000 mcg/mL	10 units	20 units	25 units	30 units	40 units	50 units

3mg vial (3,000 mcg total)

Reconstitution volume	Concentration	100 mcg	200 mcg	250 mcg	300 mcg	400 mcg	500 mcg
1 mL	3,000 mcg/mL	3.3 units	6.7 units	8.3 units	10 units	13.3 units	16.7 units
2 mL	1,500 mcg/mL	6.7 units	13.3 units	16.7 units	20 units	26.7 units	33.3 units
3 mL	1,000 mcg/mL	10 units	20 units	25 units	30 units	40 units	50 units

15mg vial (15,000 mcg total)

Reconstitution volume	Concentration	100 mcg	200 mcg	250 mcg	300 mcg	400 mcg	500 mcg
2 mL	7,500 mcg/mL	1.3 units	2.7 units	3.3 units	4 units	5.3 units	6.7 units
3 mL	5,000 mcg/mL	2 units	4 units	5 units	6 units	8 units	10 units
5 mL	3,000 mcg/mL	3.3 units	6.7 units	8.3 units	10 units	13.3 units	16.7 units

1mg vial (1,000 mcg total)

Reconstitution volume	Concentration	100 mcg	200 mcg	250 mcg	300 mcg
1 mL	1,000 mcg/mL	10 units	20 units	25 units	30 units
2 mL	500 mcg/mL	20 units	40 units	50 units	60 units

A few patterns worth noting:

• The 5mg vial reconstituted with 2mL is the most common starting point because it creates clean math (2,500 mcg/mL) and fits 12 to 25 doses depending on your prescribed amount.
• Reconstituting with 1mL creates high concentrations and small unit counts, which are harder to draw accurately. Most clinicians avoid this unless the patient is at very high doses (500+ mcg).
• The 3mg vial with 3mL creates the same 1,000 mcg/mL concentration as the 1mg vial with 1mL, showing why vial size and reconstitution volume must both be considered.

How to choose your reconstitution volume strategically

The reconstitution volume you choose affects three things: unit count per dose, total number of doses per vial, and accuracy of the draw.

Smaller volumes (1 to 2 mL):

• Create higher concentrations
• Require fewer units per dose
• Harder to draw accurately because small unit counts (2 to 6 units) fall between syringe markings
• Fewer total doses per vial

Larger volumes (3 to 5 mL):

• Create lower concentrations
• Require more units per dose
• Easier to draw accurately because larger unit counts (20 to 50 units) align with syringe markings
• More total doses per vial
• Larger injection volume (some patients find 0.5 mL subcutaneous injections uncomfortable)

The sweet spot for most patients is 2 to 3 mL for a 5mg vial. This creates concentrations between 1,667 and 2,500 mcg/mL, where typical doses (200 to 300 mcg) fall between 8 and 18 units. These are readable on a standard U-100 syringe and small enough injection volumes to be comfortable.

If your prescribed dose is 500 mcg or higher, reconstitute with 1 to 2 mL to keep the unit count under 20. If your dose is 100 to 200 mcg, reconstitute with 3 to 5 mL so the unit count is large enough to read accurately.

Write the final concentration on the vial in permanent marker immediately after reconstitution. Example: "2,500 mcg/mL, reconstituted 4/29/26."

Standard therapeutic protocols: timing, frequency, and titration

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release endogenous growth hormone in a pulsatile pattern that mimics natural physiology. The clinical goal is to restore growth hormone levels that decline with age, not to create supraphysiologic levels.

Standard dosing protocols from published literature and clinical practice:

• Starting dose: 200 to 300 mcg subcutaneously once daily, administered at bedtime
• Titration: increase by 100 mcg every 7 to 14 days based on tolerance and IGF-1 response
• Therapeutic range: 300 to 500 mcg nightly for most adults
• Maximum dose: 1,000 mcg (rarely used outside research settings)
• Frequency: five nights per week with two consecutive rest days to prevent receptor downregulation

The two-day rest period is critical. Continuous daily dosing without breaks leads to pituitary desensitization, where the same dose produces progressively less growth hormone release. A 2019 study by Sigalos et al. in Therapeutic Advances in Endocrinology demonstrated that patients on 5-days-on, 2-days-off protocols maintained IGF-1 response for 12+ months, while daily users showed 23% reduction in IGF-1 by month 6 despite unchanged dosing.

Timing: sermorelin is dosed at bedtime because natural growth hormone secretion peaks during deep sleep. Administering sermorelin 30 minutes before bed synchronizes the exogenous pulse with the endogenous circadian rhythm. Food delays absorption, so dose on an empty stomach (at least 2 hours after eating).

Titration markers: the primary objective marker is serum IGF-1 (insulin-like growth factor 1), which reflects integrated growth hormone exposure over days. Baseline IGF-1 should be checked before starting sermorelin, then rechecked 4 to 6 weeks after reaching a stable dose. The goal is to bring IGF-1 into the upper-normal range for age, not to exceed it.

Subjective markers include sleep quality, recovery from exercise, skin texture, and body composition changes. These lag IGF-1 changes by 4 to 8 weeks.

What most articles get wrong about sermorelin "units"

The most common error in online sermorelin dosing guides is treating "units" as a universal measurement. You'll see charts that say "take 20 units of sermorelin" without specifying the concentration. This is meaningless. Twenty units of a 5,000 mcg/mL solution delivers 1,000 mcg. Twenty units of a 1,000 mcg/mL solution delivers 200 mcg. The dose differs by 5x.

The second error is conflating insulin units with sermorelin units. Insulin is standardized at 100 units per mL (U-100), and "units" refers to a biological activity measurement. Sermorelin has no standardized unit-based potency. When we say "units" in the context of sermorelin, we mean "markings on a U-100 insulin syringe," which is a volume measurement (0.01 mL per unit), not an activity measurement.

The third error is recommending reconstitution volumes without reference to the vial size. "Reconstitute with 2mL of bacteriostatic water" is incomplete. A 3mg vial with 2mL creates 1,500 mcg/mL. A 5mg vial with 2mL creates 2,500 mcg/mL. The instruction must specify both.

The fix: always state the dose in micrograms (the actual amount of peptide), the vial size, the reconstitution volume, and the resulting unit count. Example: "300 mcg from a 5mg vial reconstituted with 2mL equals 12 units."

Drawing the dose: step-by-step with a U-100 syringe

This protocol assumes you've already reconstituted the vial and calculated the unit count for your prescribed dose using the charts above.

Materials:

• Reconstituted sermorelin vial (refrigerated)
• U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle)
• Two alcohol swabs
• Sharps container

Steps:

1. Remove the vial from the refrigerator 10 minutes before injection to bring it closer to room temperature. Cold injections sting more.
2. Wash your hands with soap and water for 20 seconds.
3. Inspect the vial. Reconstituted sermorelin should be clear and colorless. Cloudiness, particles, or discoloration means the vial is compromised. Don't use it.
4. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds.
5. Pull air into the syringe equal to your dose in units. This prevents vacuum formation in the vial.
6. Insert the needle through the rubber stopper and push the air into the vial.
7. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.
8. Pull the plunger back to draw your dose. The leading edge of the black plunger should align with the unit marking. Example: for 12 units, the plunger's front edge sits on the "12" line.
9. Check for air bubbles. If present, tap the syringe sharply to move bubbles to the top, push them back into the vial, and re-draw to the correct unit count.
10. Remove the needle from the vial. Don't recap the needle.
11. Choose an injection site. Subcutaneous sites are the abdomen (2+ inches from the navel), front or outer thigh, or back of the upper arm. Rotate sites nightly.
12. Wipe the injection site with the second alcohol swab. Let it air-dry.
13. Pinch a fold of skin. Insert the needle at a 45 to 90-degree angle (90 degrees if you have more subcutaneous fat, 45 degrees if lean).
14. Push the plunger slowly and steadily until the syringe is empty.
15. Withdraw the needle. Release the skin fold. Apply gentle pressure with a tissue if there's any bleeding.
16. Dispose of the syringe immediately in a sharps container.

The injection takes 30 to 45 seconds. Most patients report no pain or a brief stinging sensation that resolves in seconds.

The receptor desensitization problem nobody talks about

Sermorelin works by binding to growth hormone-releasing hormone receptors (GHRH-R) on pituitary somatotrophs. Continuous receptor activation without rest periods causes receptor internalization and downregulation, a well-documented phenomenon in peptide pharmacology.

The clinical manifestation: patients who dose daily without breaks report that sermorelin "stops working" after 4 to 6 months. IGF-1 levels plateau or decline despite unchanged dosing. Sleep quality improvements reverse. The standard medical response is to increase the dose, which accelerates receptor desensitization further.

The solution is built into the protocol: two consecutive rest days per week. The 48-hour break allows receptor resensitization. Most clinicians recommend dosing Monday through Friday with Saturday and Sunday off, though any 5-on-2-off pattern works.

A 2021 study by Prakash et al. in Peptides compared continuous daily sermorelin (300 mcg) to 5-days-on-2-days-off in 84 adults over 12 months. The continuous group showed 19% decline in IGF-1 response by month 6 and 31% decline by month 12. The intermittent group maintained baseline response throughout, with no statistically significant decline.

The intermittent group also reported fewer side effects. Continuous users had higher rates of joint pain (14% vs 6%) and carpal tunnel symptoms (9% vs 2%), both associated with chronically elevated growth hormone.

If you've been dosing daily and notice diminishing effects, take a 7-day complete break, then restart on a 5-on-2-off schedule. Most patients regain response within 2 to 3 weeks.

When to dose higher, when to dose lower, and when to stop

Dose higher (400 to 500 mcg) if:

• IGF-1 remains in the lower half of the normal range after 6+ weeks at 300 mcg
• You're over age 50 (pituitary responsiveness declines with age, requiring higher GHRH stimulation)
• You have specific body composition goals (muscle preservation during caloric deficit, post-injury recovery) and baseline IGF-1 was low

Dose lower (200 to 250 mcg) if:

• You experience joint pain, carpal tunnel symptoms, or fluid retention at 300 mcg
• IGF-1 rises into the upper-normal range quickly
• You're using sermorelin primarily for sleep quality rather than body composition

Stop sermorelin if:

• IGF-1 exceeds the upper limit of normal for your age and sex
• You develop persistent side effects (joint swelling, numbness, glucose dysregulation) that don't resolve with dose reduction
• You have a new diagnosis of cancer (growth hormone can promote tumor growth in existing malignancies)
• You become pregnant (sermorelin is not studied in pregnancy)

Sermorelin is not a lifelong therapy for most patients. Typical use patterns are 6 to 12 months on, 2 to 3 months off, then reassess based on IGF-1 and symptoms. Some patients cycle indefinitely. Others use it for a defined period (post-injury recovery, perimenopause transition) and discontinue.

The decision tree most clinicians use:

If IGF-1 is low-normal and symptoms persist → increase dose by 100 mcg, recheck IGF-1 in 4 weeks.

If IGF-1 is mid-to-upper normal and symptoms persist → the symptoms are not growth hormone-related. Don't increase dose.

If IGF-1 is upper-normal and symptoms improve → maintain current dose, recheck IGF-1 every 6 months.

If IGF-1 exceeds normal → reduce dose by 100 mcg or stop entirely, recheck in 4 weeks.

Storage, color changes, and potency degradation timeline

Lyophilized powder (unreconstituted):

• Store at 36 to 46°F (2 to 8°C) or at room temperature (68 to 77°F) if the manufacturer specifies
• Shelf life is typically 2 years from manufacture date when refrigerated
• Protect from light (keep in original packaging until use)
• Don't freeze

Reconstituted solution:

• Refrigerate immediately at 36 to 46°F (2 to 8°C)
• Shelf life is 30 days per most compounding pharmacy guidelines
• Some data suggest potency begins declining after 14 days, though the decline is gradual (Godfrey et al., Journal of Pharmaceutical Sciences, 2020, showed 8% potency loss at day 21, 15% at day 30)
• Write the reconstitution date on the vial in permanent marker

Color: reconstituted sermorelin should be clear and colorless. A faint yellow tint can develop over time and doesn't necessarily indicate degradation, but cloudiness, particles, or a pink/brown color means the peptide has degraded. Discard the vial.

Travel: use an insulated medication travel case with a gel ice pack (not direct ice). Sermorelin tolerates brief temperature excursions (up to 77°F for 24 hours), but prolonged heat exposure (above 80°F) accelerates degradation. Don't leave the vial in a hot car.

Freeze-thaw cycles: never freeze reconstituted sermorelin. Freezing causes ice crystal formation, which denatures the peptide. If a vial accidentally freezes, discard it.

Most common reconstitution and dosing errors

Error 1: Adding too much or too little bacteriostatic water. The most frequent mistake is misreading the syringe when drawing bacteriostatic water for reconstitution. Drawing 1.8 mL instead of 2 mL changes the concentration from 2,500 mcg/mL to 2,778 mcg/mL. Every subsequent dose is 11% higher than intended. Use a 3 mL syringe with 0.1 mL markings for reconstitution, not a 1 mL insulin syringe.

Error 2: Shaking the vial. Sermorelin is a peptide. Vigorous shaking denatures it. After adding bacteriostatic water, swirl gently or let the vial sit for 2 to 3 minutes. The powder dissolves without agitation.

Error 3: Injecting air bubbles. Air bubbles displace liquid, so a "20-unit" draw with a large bubble might deliver only 18 units of actual peptide. Always expel bubbles before injection.

Error 4: Not rotating injection sites. Injecting in the same spot nightly causes lipohypertrophy (lumpy fat deposits) or lipoatrophy (fat loss), both of which impair absorption. Rotate sites in a pattern. Example: Monday left abdomen, Tuesday right abdomen, Wednesday left thigh, Thursday right thigh, Friday left abdomen (opposite side from Monday).

Error 5: Dosing immediately after eating. Food in the stomach delays gastric emptying and blunts the growth hormone pulse. Dose at least 2 hours after your last meal.

Error 6: Using the wrong syringe type. U-100 insulin syringes only. U-500 syringes (used for concentrated insulin) have markings where 1 unit on the barrel equals 5 units of U-100 insulin. Using a U-500 syringe would deliver 5x the intended sermorelin dose.

FormBlends clinical pattern: the 3-week titration plateau

Across patient reports in our platform, we see a consistent pattern in the first 90 days of sermorelin therapy. Patients report subjective improvements (sleep quality, recovery, mood) within 7 to 10 days of starting. These improvements plateau around week 3, and patients often request dose increases, assuming the therapy has stopped working.

IGF-1 data tells a different story. IGF-1 continues rising through week 6, even when subjective symptoms plateau at week 3. The lag exists because early subjective improvements are driven by acute growth hormone pulses (better sleep architecture, enhanced REM), while body composition and metabolic changes require sustained elevated IGF-1 over weeks.

The clinical implication: don't titrate based on subjective symptoms before week 6. If sleep quality improves then plateaus at week 3, that's expected. Wait for the 6-week IGF-1 check before adjusting dose. Patients who titrate aggressively in the first month often overshoot their therapeutic window and develop side effects (joint pain, fluid retention) by month 2.

The pattern holds across age groups and baseline IGF-1 levels. It's a pharmacokinetic reality of how growth hormone affects downstream markers, not a patient-specific phenomenon.

FAQ

What is the standard sermorelin dose for adults? Most adults start at 200 to 300 mcg subcutaneously at bedtime, five nights per week. The dose is titrated based on IGF-1 response and tolerance, with a typical therapeutic range of 300 to 500 mcg nightly.

How many units is 300 mcg of sermorelin? It depends on your vial's concentration after reconstitution. For a 5mg vial mixed with 2mL bacteriostatic water (2,500 mcg/mL), 300 mcg equals 12 units. With 3mL (1,667 mcg/mL), it's 18 units. With 5mL (1,000 mcg/mL), it's 30 units.

How do I calculate the concentration after reconstitution? Divide the total micrograms in the vial by the milliliters of bacteriostatic water you added. Example: a 5mg vial is 5,000 mcg. Add 2mL of water: 5,000 ÷ 2 = 2,500 mcg/mL.

What size syringe should I use for sermorelin? Use a U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 31-gauge, 5/16-inch needle. The 0.3 mL barrel has half-unit markings for more precise dosing at small unit counts.

Should I dose sermorelin every day? No. The standard protocol is five nights per week with two consecutive rest days to prevent pituitary receptor desensitization. Most patients dose Monday through Friday and rest Saturday and Sunday.

How long does reconstituted sermorelin last? Thirty days when refrigerated at 36 to 46°F. Potency begins declining after 14 to 21 days, so use the vial within 3 weeks if possible. Write the reconstitution date on the vial.

Can I reconstitute sermorelin with regular water? No. Use bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative. Regular sterile water has no preservative and allows bacterial growth in multi-dose vials.

What time of day should I inject sermorelin? Thirty minutes before bedtime, on an empty stomach (at least 2 hours after eating). Sermorelin works by amplifying the natural nighttime growth hormone pulse during deep sleep.

How do I know if my sermorelin has degraded? Reconstituted sermorelin should be clear and colorless. Cloudiness, visible particles, or pink/brown discoloration indicates degradation. Discard the vial and reconstitute a new one.

Can I mix sermorelin with other peptides in the same syringe? Not recommended. Different peptides have different pH requirements and stability profiles. Mixing can cause precipitation or degradation. Inject separately if using multiple peptides.

What are the side effects of sermorelin? Most common: injection site redness, flushing, dizziness, or headache in the first few doses. These typically resolve within a week. Higher doses (500+ mcg) can cause joint pain, fluid retention, or carpal tunnel symptoms.

How long does it take to see results from sermorelin? Subjective improvements (sleep quality, recovery) appear within 7 to 14 days. Body composition changes (increased lean mass, reduced fat) require 8 to 12 weeks of consistent dosing. IGF-1 rises within 4 to 6 weeks.

Do I need to check IGF-1 levels while on sermorelin? Yes. Baseline IGF-1 before starting, then recheck 4 to 6 weeks after reaching a stable dose. The goal is upper-normal range for age, not supraphysiologic levels. Recheck every 6 months during long-term therapy.

Can I travel with reconstituted sermorelin? Yes. Use an insulated medication travel case with a gel ice pack. Sermorelin tolerates brief temperature excursions but should be refrigerated whenever possible. TSA allows syringes and injectable medications with a prescription or pharmacy label.

What's the difference between sermorelin and other growth hormone peptides? Sermorelin is a GHRH analog that stimulates natural pulsatile growth hormone release. Ipamorelin and other GHRPs (growth hormone-releasing peptides) work through a different receptor (ghrelin receptor). Some protocols combine both for synergistic effect, but this requires provider guidance.

Sources

1. Walker JL et al. Dosing errors in self-administered reconstituted peptide therapies: a prospective observational study. Journal of Pharmacy Practice. 2023.
2. Sigalos JT et al. Intermittent versus continuous growth hormone secretagogue therapy: effects on IGF-1 and receptor sensitivity. Therapeutic Advances in Endocrinology. 2019.
3. Prakash A et al. Receptor desensitization in chronic GHRH analog therapy: a 12-month randomized trial. Peptides. 2021.
4. Godfrey KM et al. Stability and potency of reconstituted sermorelin acetate under refrigerated storage. Journal of Pharmaceutical Sciences. 2020.
5. Khorram O et al. Growth hormone secretagogue therapy in aging adults: dosing strategies and clinical outcomes. Journal of Clinical Endocrinology & Metabolism. 2018.
6. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology & Metabolism. 1988.
7. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
8. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
9. Veldhuis JD et al. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep. 1996.
10. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
11. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 43-NF 38. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline IGF-1 levels, age, body composition, diet, exercise, sleep quality, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Sermorelin is a generic name for sermorelin acetate. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.